Personalized Immunotherapy Platform Approved for Phase II Expansion Trial
A joint modeling platform based on patient tumor neoantigen profiles and gut immune maps significantly extends progression-free survival in solid tumor Phase II trials.
Trial Design
The expansion trial enrolled 412 advanced solid tumor patients covering gastric cancer, pancreatic cancer, and triple-negative breast cancer. The platform completes within 72 hours: whole exome sequencing, HLA typing, neoantigen priority ranking, and joint modeling of fecal microbiome and serum cytokine panels.
"The immune system isn't a static switch - it's a network that evolves with treatment. Our algorithm calculates 'which axis to activate right now'." — Liu Wei, Director, Clinical Immunoinformatics Center
Key Endpoint Data
Interim analysis (median follow-up 11 months) shows:
- Median progression-free survival (mPFS): 8.4 months (control group 4.1 months)
- Grade 3-4 immune-related adverse events: 14% (vs. ~22% in historical immunotherapy monotherapy cohort)
- Biomarker response: In patient subgroups with gut microbiota α-diversity above threshold, objective response rate increased to 41%
Regulatory Innovation
For the first time, regulators accepted digital twin reports as supplementary materials: the system replays dosing trajectories on virtual patient populations, showing toxicity distribution in extreme scenarios.
Industry Impact
Three multinational pharmaceutical companies and two domestic PD-1 manufacturers have signed API-level data interoperability agreements, planning to integrate the platform with real-world data registries in 2028.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.